Anal, Rectal (e.g., Suppositories, Etc.) Patents (Class 424/436)
  • Patent number: 6500461
    Abstract: This invention provides vehicles capable of delivering high concentrations of poorly hydrophilic/poorly lipophilic compounds to animals, by combining compounds having biocompatible hydrophobic domains with conjugates having both hydrophobic and hydrophilic regions. Such formulations are suitable for a number of uses in animals, particularly the administration thereto of high concentrations of therapeutically useful compound, without an undue level of side effects.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: December 31, 2002
    Assignee: The Liposome Company
    Inventors: Walter Perkins, Xingong Li, Donald Hirsh, Eric Mayhew, Imran Ahmad, Shaukat Ali, Andrew Janoff
  • Patent number: 6491942
    Abstract: The present invention provides a suppository comprising a hydrophobic hydroxypropyl methylcellulose. The present invention is useful as a suppository base which has little interaction with a drug and has an excellent retainability.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: December 10, 2002
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Tomoko Fujimori, Kimiko Sugita
  • Patent number: 6488954
    Abstract: The present invention relates to a liquid suppository composition comprising diclofenac sodium, poloxamer and at least one polymer select from the group consisting of polyethylene oxide and polyvinylpyrrolidone. The composition provides the advantages of. (1) a feel of foreign matter or discomfort does not occur when the composition is rectally administered; and (2) administration is easy and after rectal administration, the composition is neither leaked out from the anus nor shifted into the end of large intestine.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: December 3, 2002
    Assignee: Dong Wha Pharm. Ind. Co., Ltd.
    Inventors: Sung June Yoon, Jei Man Ryu, Jae Hee Jung, Su Jin Cho
  • Patent number: 6479045
    Abstract: The present invention concerns compositions and methods for preventing miscarriage and premature labor, and for treating and preventing Bacterial Vaginosis using a pH-buffering polymer. The present invention further concerns formulating such a composition or method in such a way as to provide therapeutically sufficient levels of the composition to a patient in need thereof.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: November 12, 2002
    Assignee: Columbia Laboratories, Inc.
    Inventors: William J. Bologna, Howard L. Levine
  • Publication number: 20020164374
    Abstract: Biodegradable polymeric implants can provide a safe and efficient means to deliver drugs in the treatment of various diseases. Although a polymeric drug delivery system can be implanted as a solid device within a subject, it is also possible to administer such a system as an injectable liquid which solidifies in vivo. An improved formulation of a polymeric drug delivery system comprises a water insoluble copolymer that is a solid or wax at 37° C., a water soluble polymer that is a liquid at 25° C., and a hydrophobic drug. These drug delivery systems can be administered by injection, and do not require the use of a toxic curing agent or inconvenient temperature manipulations.
    Type: Application
    Filed: October 28, 1998
    Publication date: November 7, 2002
    Inventors: JOHN JACKSON, XICHEN ZHANG, HELEN BURT
  • Patent number: 6476059
    Abstract: The invention relates to the use of polycyclic 2-aminothiazole systems and their physiologically tolerated salts and physiologically functional derivatives for the treatment of obesity. The treatment involves administration of a compound of formula I, in which the radicals have the stated meanings, and of their physiologically tolerated salts and physiologically functional derivatives.
    Type: Grant
    Filed: February 10, 2000
    Date of Patent: November 5, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jähne, Karl Geisen, Hans-Jochen Lang, Martin Bickel
  • Patent number: 6464992
    Abstract: The invention involves methods and compositions useful in delivering micronutrients to cells. By formulating the micronutrient in the form of an ester that is convertible to the active form of the micronutrient, one can combine it with a co-ester that inhibits esterases, so that the micronutrient can reach the targeted cells prior to degradation. Both methods and compositions are described.
    Type: Grant
    Filed: April 11, 2001
    Date of Patent: October 15, 2002
    Assignee: University of Kentucky Research Foundation
    Inventors: Elaine L. Jacobson, Myron K. Jacobson, Jaber G. Qasem, Hyuntae Kim, Moonsun Kim
  • Patent number: 6451848
    Abstract: The present invention relates to a pharmaceutical composition which includes morphine gluconate or chemical equivalent thereof. In one embodiment, the present invention includes a method of making morphine gluconate or chemical equivalent thereof by mixing morphine sulfate with sodium gluconate. The present invention also includes a method for eliciting an analgesic or anesthetic response in a mammal which includes administering a therapeutically effective amount of a pharmaceutical composition including morphine gluconate or chemical equivalent thereof.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: September 17, 2002
    Assignee: Nastech Pharmaceutical Company, Inc.
    Inventors: Charanjit R. Behl, Vincent D. Romeo, Anthony P. Sileno
  • Patent number: 6451779
    Abstract: A composition with three hormone components is administered to a mammal to cause the suppression or cessation of the menstruation cycle. Alternatively, it can be administered for treatment of tumors of the mammary gland. The composition contains at least a synthetic estrogen, a biogenetic estrogen, and a gestagen. Alternatively, the composition can include hormones which upon ingestion are metabolized to the above-mentioned hormones.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: September 17, 2002
    Inventor: Rolf-Dieter Hesch
  • Patent number: 6447806
    Abstract: Particles of a substantially water insoluble biologically active substance, such as Cyclosporin, are loaded with a charged glyceryl ester as an electrostatic stabilizer which imparts to the particles a zeta potential and having an active substance:stabilizer weight ratio of 1:1 to 400:1 and an average particle diameter of 1 nanometer to 10 micrometers. Compositions having such particles are found to be useful delivery systems.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: September 10, 2002
    Assignee: Novartis AG
    Inventors: Peter Gassmann, Heinz Sucker
  • Patent number: 6432446
    Abstract: A method of treating disorders involving the urethrogentical tract by administering to pateints in need therof therapeutically effective amounts of the desethyl metabolite of oxybutynin and/or the optically active isomers thereof, which are free from said cardiac side effect of oxybutynin, while maintaining the therapeutic activities of oxybutynin or the optically active isomers thereof.
    Type: Grant
    Filed: February 1, 2001
    Date of Patent: August 13, 2002
    Assignee: Bridge Pharma, Inc.
    Inventor: A. K. Gunnar Aberg
  • Patent number: 6432440
    Abstract: Liquid pharmaceutical compositions for administration to a mucosal surface, comprising a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: August 13, 2002
    Assignee: West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited
    Inventors: Peter James Watts, Lisbeth Illum
  • Patent number: 6426084
    Abstract: Methods for treating specific patient groups for sexual dysfunction are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions in patients who are free of cardiac disease and/or who have not been given organic nitrates.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: July 30, 2002
    Inventor: Neal R. Cutler
  • Patent number: 6420336
    Abstract: The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: July 16, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Michael R. Boyd
  • Patent number: 6416780
    Abstract: This invention relates to an intravaginal shell or core drug delivery device suitable for administration to female humans or animals comprises testosterone or a testosterone precursor in a polymer matrix, surrounded by a sheath, and is capable of releasing the testosterone or testosterone precursor in a substantially zero-order pattern on a daily basis for at least three weeks. The device is intended to restore circulating testosterone levels to the normal physiol, range or to induce supratherapeutic testosterone levels.
    Type: Grant
    Filed: May 1, 2000
    Date of Patent: July 9, 2002
    Assignee: Galen (Chemicals) Limited
    Inventors: Clare Passmore, Claire Gilligan
  • Patent number: 6406710
    Abstract: The present invention relates to complexes between (1) a target-binding moiety; (2) a cavity-forming moiety; and (3) a pharmacological compound to be delivered to a target, wherein the pharmacological compound is buried inside of the cavity-forming moiety, but not covalently bound to either the target-binding moiety or the cavity-forming moiety. The complexes of thus invention may be used as to deliver a pharmacological compound to cells, tissues, organs, viruses, microorganisms or other surfaces that are characterized by an entity that binds the target-binding moiety portion of the complex. The present invention also relates to pharmaceutical compositions comprising the non-covalent complexes of this invention. The invention also relates to methods of delivering a pharmacological compound to a target in a patient. The present invention also relates to the use of the complexes of this invention for the separation of chemical entities from their chiral forms or contaminants.
    Type: Grant
    Filed: July 16, 1998
    Date of Patent: June 18, 2002
    Inventor: Nikos Panayotatos
  • Patent number: 6395273
    Abstract: Methods are described for treating inflammatory bowel disease in animals, including humans. Specific avian polyclonal antibodies directed to TNF are shown to have a beneficial effect in animal models predictive of human therapy for the treatment of colitis.
    Type: Grant
    Filed: June 10, 1998
    Date of Patent: May 28, 2002
    Assignee: Promega Corporation
    Inventors: John A. Kink, Katherine L. Worledge, Douglas C. Stafford
  • Patent number: 6383514
    Abstract: A hypocholesterolemic composition, for use in reducing serum cholesterol levels in warm-blooded organisms, the composition containing: (a) a phytostanol ester and (b) a tocopherol.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: May 7, 2002
    Assignee: Henkel Kommanditgesellschaft auf Aktien
    Inventors: Norbert Weitkemper, Bernd Fabry
  • Patent number: 6383510
    Abstract: Acid-labile active compounds are prepared in suppository form, particularly for rectal administration.
    Type: Grant
    Filed: July 6, 2000
    Date of Patent: May 7, 2002
    Assignee: Byk Gulden Lomberg Chemische Fabrik GmbH
    Inventors: Rudolf Linder, Rango Dietrich
  • Patent number: 6383471
    Abstract: The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compositions by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compositions of the invention are particularly suitable for use in oral dosage forms.
    Type: Grant
    Filed: April 6, 1999
    Date of Patent: May 7, 2002
    Assignee: Lipocine, Inc.
    Inventors: Feng-Jing Chen, Mahesh V. Patel
  • Patent number: 6375963
    Abstract: The present invention includes a hot-melt extruded film and method of preparation thereof. The film is made from a precursor composition containing at least a water soluble or water swellable thermoplastic polymer, preferably HPC and/or PEO, and a bioadhesive polymer. The film can also contain a therapeutic agent, preservative, buffering agent, antioxidant, super-disintegrant or absorbent, flavorant, colorant, water insoluble polymer, organic acid, surfactant, film modifier, and/or cross-linking agent. The film does not contain a conventional plasticizer or a material which is generally recognized in the art as a plasticizer for extruded films. The film can be sized and shaped to provide a controlled delivery of a therapeutic agent to the buccal, rectal, uterine, vaginal, abdominal, cranial, ophthalmic, nasal, sinus, or otic cavities. The film can also be used for the treatment of wounds.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: April 23, 2002
    Inventors: Michael A. Repka, Staci L. Repka, James W. McGinity
  • Patent number: 6375976
    Abstract: The invention relates to solutions containing acidic compositions that have a pH of less than 1, are non-caustic to human tissue and are safe for human ingestion. These compositions may be used as the sole or major component of solutions such as cleansers, pharmaceuticals, food preservatives and disinfectants. The acidic compositions may be used in medical, industrial, military and household applications. The invention also relates methods of administering and using the acidic compositions of the invention.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: April 23, 2002
    Assignee: SteriFx, Inc.
    Inventors: Ernest G. Roden, John R. Dankert
  • Patent number: 6375988
    Abstract: This invention relates to a drug composition with a controlled drug release rate. The drug composition comprises: a matrix formed of the following ingredients (a) and (b): (a) a biodegradable, biocompatible high-molecular substance and/or polyvalent metal ions or polyvalent metal ion source, and (b) hyaluronic acid or a salt thereof; and a drug incorporated as an ingredient (c) in said matrix. The drug composition has biodegradability and biocompatibility, permits easy control of a release rate of the drug, and can persistently exhibit its pharmacological effect over a long time.
    Type: Grant
    Filed: October 14, 1998
    Date of Patent: April 23, 2002
    Assignee: SSP Co., Ltd.
    Inventors: Makoto Suzuki, Kenji Ishigaki, Minoru Okada, Kenji Ono, Shuichi Kasai, Katsumi Imamori
  • Patent number: 6368586
    Abstract: Methods and compositions are provided for enhancing the bioadhesive properties of polymers used in drug delivery devices. The bioadhesive properties of a polymer are enhanced by incorporating a anhydrideoligome into the polymer to enhance the ability of the polymer to adhere to a tissue surface such as a mucosal membrane. Anhydrideoligomes which enhance the bioadhesive properties of a polymer include water-insoluble anhydrideoligomes such as water-insoluble metal oxides, including oxides of calcium, iron, copper and zinc. The anhydrideoligomes can be incorporated within a wide range of polymers including proteins, polysaccharides and synthetic biocompatible polymers. In one embodiment, metal oxides can be incorporated within polymers used to form or coat drug delivery devices, such as microspheres, which contain a drug or diagnostic agent.
    Type: Grant
    Filed: March 27, 2000
    Date of Patent: April 9, 2002
    Assignee: Brown University Research Foundation
    Inventors: Jules S. Jacob, Edith Mathiowitz
  • Patent number: 6352721
    Abstract: Delivery devices capable of delivering one or more active substances by diffusion through plural micropores in the membrane or by osmotic pumping through one or more preformed passageways in the membrane are provided. The device has an about centrally located expandable core completely surrounded by an active substance-containing layer, which is completely surrounded by the membrane. The device is capable of delivering insoluble, slightly soluble, sparingly soluble and very soluble active substances to an environment of use. The preferred delivery rate is zero order. The device can deliver an active substance for a period of about 12-24 hours.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: March 5, 2002
    Assignee: Osmotica Corp.
    Inventor: Joaquina Faour
  • Patent number: 6348208
    Abstract: Methods and pharmaceutical compositions for using desmethylselegiline. In particular, the present invention provides novel compositions and methods for using desmethylselegiline for selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Desmethylselegiline is the R-(−) enantiomer of N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane. Claimed compositions include both the R-(−) isomer and mixtures of the R-(−) and S(+) isomers. Pharmaceutically acceptable acid addition salts may also be used. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.
    Type: Grant
    Filed: July 12, 1996
    Date of Patent: February 19, 2002
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventors: Cheryl D. Blume, Anthony R. DiSanto
  • Patent number: 6340457
    Abstract: Pharmaceutical and alimentary compositions containing Acetobacter xylinum as the active ingredient for the treatment of gastroenteral dysmicrobisms, gastroenteral acute and chronic infections and impairments of the gastroenteral functionality.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: January 22, 2002
    Assignee: Farmilia Farmaceutici Milano S.R.L.
    Inventors: Adriano Andriolli, Fausto Panni
  • Patent number: 6335038
    Abstract: A composition that may take the form of a dietary supplement or of a medicament is disclosed which comprises as active ingredients propionyl L-carnitine and the isoflavone genistein for the therapeutic treatment of osteoporosis and menopause syndrome.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: January 1, 2002
    Assignee: Sigma-Tau Healthscience S.p.A.
    Inventor: Claudio Cavazza
  • Patent number: 6333046
    Abstract: To provide a transmucous absorption enhancer comprising a medium-chain fatty acid salts or a bile acid salt and a glycyrrhizic acid salts capable of sustaining the effect of the absorption enhancer and allowing an agent (especially a physiologically active peptide) to be absorbed via a mucosa (especially a large intestine mucosa).
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: December 25, 2001
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Michinori Sakai, Hiroshi Ohtake, Hidekazu Azuma, Masaki Otagiri, Teruko Imai
  • Publication number: 20010053379
    Abstract: This invention pertains to a method that can control, treat, and prevent Diabetes Mellitus. The method includes means of administering a potent product, including mainly the active ingredient Linalool, in any one of several forms, alone or with other additives and catalysts, such as vitamin E to enable the body to handle and control, then correct the complications of Diabetes Mellitus. A modest percentage of users suffering from this disease can be cured completely while the majority of others improve remarkably and experience lower blood glucose and reduce the glycated hemoglobin HbAlc readings to what are medically acceptable and healthy levels. Others, who are vulnerable to the disease due to hereditary factors, or other reasons, can help prevent it. The method works in several ways, including activation of the pancreas and re-establishing the ability of body cells to utilize and handle better and well, the glucose in the blood, and regulate the level of natural insulin in the body.
    Type: Application
    Filed: January 2, 2001
    Publication date: December 20, 2001
    Applicant: DIABEX INC.
    Inventors: Osama Mansour Murad, Husni Abu Seir, Hafez Taji Farouqi
  • Patent number: 6326023
    Abstract: The present invention relates to a synergistic formulation comprising pharmaceutically effective amount of &agr;/&bgr; arteether and a neutralized refined vegetable oil suitable for administration by rectal route, method for the treatment of cerebral and comatose malaria and process for the preparation of the said formulation.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: December 4, 2001
    Assignee: Council of Scientific & Industrial Research
    Inventors: Guru Prakash Dutta, Dharam Chand Jain, Ranjendra Singh Bhakuni, Sudhanshu Saxena, Sangeeta Dhawan, Suman Preet Singh Khanuja, Sushil Kumar, Renu Tripathi, Aseem Umesh, Nuzhat Kamal, Anil Kumar Dwivedi, Satyawan Singh
  • Patent number: 6319514
    Abstract: The present invention provides a method for eliciting an onset hastened analgesic and anti-inflammatory response and combating nausea in acute migraine attacks. This method comprises administering a pharmaceutical composition comprising more than one active ingredient, wherein said more than one active ingredient consist essentially of: (i) domperidone or an analogue thereof in an amount sufficient to hasten the onset of the analgesic and anti-inflammatory response and to combat nausea in an acute migraine attack, and (ii) a NSAID, a pharmaceutically acceptable salt thereof or a pure (−) or pure (+) optical isomeric form thereof in an analgesically and anti-inflammatory effective amount, wherein said NSAID is selected from the group consisting of proprionic acid derivatives, acetic acid derivatives, fenamic acid derivatives, biphenylcarboxylic acid derivatives and oxicams.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: November 20, 2001
    Assignee: The Boots Company, PLC
    Inventor: Ninh On
  • Patent number: 6310103
    Abstract: The S-isomer of a compound represented by the following formula: and pharmaceutically acceptable salts thereof is disclosed as being useful for treating urinary disorders, including urinary incontinence, and gastrointestinal disorders, including gastrointestinal hyperativity.
    Type: Grant
    Filed: January 11, 1999
    Date of Patent: October 30, 2001
    Assignee: Bridge Pharma, Inc.
    Inventor: Gunnar Aberg
  • Patent number: 6306845
    Abstract: The present invention provides a method for treating a demyelinating disease in a subject which includes administering to the subject a therapeutically effective amount of a high affinity neuromodulatory Na,K-ATPase so as to treat the demyelinating disease.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: October 23, 2001
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Vincent P. Butler, Jr.
  • Patent number: 6303147
    Abstract: The present invention is concerned with bioadhesive pharmaceutical compositions comprising a pharmaceutically effective amount of an active ingredient, from 80% to 98.8% (w/w/) pre-gelatinized starch, and from 1% to 10% (w/w) of a hydrophilic matrix forming polymer, characterized in that the composition further comprises from 0.2% to 5% (w/w) alkaliC16-22alkyl fumarate as a lubricant; solid dosage forms such as tablets which are suitable for oral, nasal, rectal and vaginal administration; processes of preparing the compositions and solid dosage forms.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: October 16, 2001
    Assignee: Janssen Pharmaceutica, N.V.
    Inventor: Paul Marie Victor Gilis
  • Publication number: 20010016716
    Abstract: A method of delivering one or more therapeutic agents comprising providing a suppository comprising one or more therapeutic agents and a biocompatible carrier medium and shaped to be capable of cooperating with the periurethral musculature to retain the suppository in place in the urethra, inserting the suppository into the urethra, and retaining the suppository within the urethra by the action of the periurethral musculature for a period of time sufficient to permit the therapeutic agent to diffuse substantially into the urethra, the referred suppository comprising a shaft having a first end and a second end and shaped to be capable of cooperating with the action of the periurethral musculature to retain the suppository within the urethra and a substantially ellipsoidal knob extending from the second end of the shaft and sized to prevent insertion into the urethra.
    Type: Application
    Filed: September 9, 1998
    Publication date: August 23, 2001
    Inventor: S. GRANT MULHOLLAND
  • Patent number: 6277396
    Abstract: A dietary supplement system having a daytime component and a nighttime component is provided, wherein the daytime component comprises at least one thermogenic substance and the nighttime component comprises at least one adrenal support substance.
    Type: Grant
    Filed: May 11, 2000
    Date of Patent: August 21, 2001
    Assignee: Maximum Human Performance, Inc.
    Inventor: Gerard Dente
  • Patent number: 6270789
    Abstract: The present invention provides a base for suppository comprising oily or fatty base and polyethlene. The suppository prepared by the use of the base of the present invention has superior heat resistance which should not cause quality deterioration such as deformation and cracks, and shows good release, internal absorbability, safety and like compared to those of the suppositories used thus so far in the applied region.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: August 7, 2001
    Assignee: Amato Pharmaceutical Products, Ltd.
    Inventors: Teruyuki Sameshima, Kengo Omachi, Izumi Fukuda
  • Patent number: 6267985
    Abstract: The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a triglyceride and a carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the triglyceride and surfactants. An optional therapeutic agent can be incorporated into the composition, or can be co-administered with the composition. The invention also provides methods of enhancing triglyceride solubility and methods of treatment with therapeutic agents using these compositions.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: July 31, 2001
    Assignee: Lipocine Inc.
    Inventors: Feng-Jing Chen, Mahesh V. Patel
  • Patent number: 6264960
    Abstract: The claimed invention pertains to methods for treating a patient who is at risk for a vascular (e.g., cardiovascular, cerebrovascular) event comprising administering to the patient an effective amount of a lipid-modifying drug. The claimed methods are particularly effective in patients having a lipid profile comprising a low Low Density Lipoprotein and a low High Density Lipoprotein.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: July 24, 2001
    Inventors: Sander J. Robins, Hanna Bloomfield Rubins, Dorothea Collins
  • Patent number: 6258374
    Abstract: The invention provides a pharmaceutical composition for rectal or vaginal administration which comprises at least two parts wherein the composition comprises (i) two or more physiologically acceptable substances each in separate parts of the composition which are such that on admixture they react to produce a physiologically acceptable gas; (ii) in at least one part of the composition a polymer stabiliser which is adapted to facilitate the formation of a water-soluble collapsible foam structure; and (iii) in at least one part of the composition a pharmaceutically active substance; an its use in the treatment or prophylaxis of disorders of the intestines, rectum or vagina.
    Type: Grant
    Filed: September 24, 1998
    Date of Patent: July 10, 2001
    Assignee: Astra Aktiebolag
    Inventors: Stefan Friess, Harald Heckenmüller, Heike Kublik, Oliver Szambien
  • Patent number: 6248324
    Abstract: The present invention discloses a composition for dermatological infections by the use of a lytic enzyme in a carrier suitable for topical application to dermal tissues. The method for the treatment of dermatological infections comprises administering a composition comprising effective amount of a therapeutic agent, with the therapeutic agent comprising a lytic enzyme produced by infecting a bacteria with phage specific for that bacteria.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: June 19, 2001
    Inventors: Vincent Fischetti, Lawrence Loomis
  • Patent number: 6248363
    Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.
    Type: Grant
    Filed: November 23, 1999
    Date of Patent: June 19, 2001
    Assignee: Lipocine, Inc.
    Inventors: Mahesh V. Patel, Feng-Jing Chen
  • Patent number: 6248789
    Abstract: The present invention is directed to the transmucosal, transdermal or oral administration of ketamine, either alone or in combination with other pain medications, to manage and treat pain and to reduce drug dependency in a subject.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: June 19, 2001
    Inventor: Stuart L. Weg
  • Patent number: 6242000
    Abstract: The use of S(−)sodium 2-(4-isobutylphenyl)propionate (the sodium salt of S(+)-ibuprofen) in pharmaceutical compositions for the treatment of inflammation, pain and pyrexia is described. Preferred compositions comprise S(−)sodium 2-(4-isobutylphenyl)propionate dihydrate. Processes to prepare S(−)sodium 2-(4-isobutyl-phenyl)propionate and its use in a process to prepare S(+) 2-(4-isobutylphenyl)propionic acid of high enantiomeric purity are also described.
    Type: Grant
    Filed: October 2, 1997
    Date of Patent: June 5, 2001
    Assignee: The Boots Company PLC
    Inventors: Bernard John Armitage, John Francis Lampard, Alan Smith
  • Patent number: 6238689
    Abstract: A delayed and sustained release composition of an additive and/or toxic agent such as nicotine is delivered systemically in therapeutic amounts while avoiding the peak plasma levels which gives rise to addiction and/or toxic side effects. The composition is delivered for absorption predominantly from the colon.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: May 29, 2001
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: John Rhodes, Brian K. Evans, Peter Rhodes, William J. Sandborn
  • Patent number: 6238661
    Abstract: Compositions and methods for the prophylactic and therapeutic treatment of bacterial infections are disclosed which comprise administering to an individual an effective amount of a composition comprising an effective amount of lytic enzyme and a carrier for delivering the lytic enzyme. This method and composition can be used for the treatment of upper respiratory infections, skin infections, wounds, burns, vaginal infections, eye infections, intestinal disorders and dental problems.
    Type: Grant
    Filed: April 18, 2000
    Date of Patent: May 29, 2001
    Assignee: New Horizons Diagnostics Corp.
    Inventors: Vincent Fischetti, Lawrence Loomis
  • Patent number: 6231882
    Abstract: A mixed micellar pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal C8 to C22 alkyl sulphate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof. The amount of each absorption enhancing compound is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt./wt. % of the formulation.
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: May 15, 2001
    Assignee: Generex Pharmaceuticals Inc.
    Inventor: Pankaj Modi
  • Patent number: 6228387
    Abstract: A first composition for topical application and a second for oral administration, make up a comprehensive program for the treatment and relief of hemorrhoids. The topical application composition contains supplements for healing of hemorrhoids including an agent for the enhancement of the formation of collagen and elastin, an antioxidant having a proanthocyanidin as the active agent in combination with vitamin C, one or more anti-inflammatory agents, and vitamin E. In the preferred embodiment, the composition is made from gotu kola extract, grape seed extract, horse chestnut extract, aloe vera, vitamin C, and vitamin E. A few drops each of Essential Oils of Chamomile and Lavender may be included. The composition may be formulated as an ointment, cream or gel for external application. The components of the composition work synergistically to relieve the pain, discomfort and swelling associated with hemorrhoids while enhancing the connective tissue sheathes surrounding and supporting the veins and capillaries.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: May 8, 2001
    Inventor: Murray Borod
  • Patent number: 6225343
    Abstract: The present invention relates to a pharmaceutical composition which includes morphine gluconate or chemical equivalent thereof. In one embodiment, the present invention includes a method of making morphine gluconate or chemical equivalent thereof by mixing morphine sulfate with sodium gluconate. The present invention also includes a method for eliciting an analgesic or anesthetic response in a mammal which includes administering a therapeutically effective amount of a pharmaceutical composition including morphine gluconate or chemical equivalent thereof.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: May 1, 2001
    Assignee: Nastech Pharmaceutical Company, Inc.
    Inventors: Charanjit R. Behl, Vincent D. Romeo, Anthony P. Sileno